Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

Yvonne M H Versleijen-JonkersMelissa H S Hillebrandt-RoeffenLaurens van HoudtEmmy D G FleurenWinette T A van der GraafYvonne M H Versleijen-Jonkers

Published in: Targeted oncology (2018)

This study shows that monotherapy with an ALK inhibitor, such as ceritinib, in RMS, has no effect on ALK signaling. However, the synergistic effects of ceritinib and dasatinib are promising, most probably due to targeting of IGF1R and Src.

Keyphrases

advanced non small cell lung cancer
cancer therapy
tyrosine kinase
epidermal growth factor receptor
diffuse large b cell lymphoma
drug delivery
cell proliferation
binding protein
protein kinase
double blind